An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic

• Autor(a) principal: Paula,H.S.C.
• Data de Publicação: 2022
• Outros Autores: Santiago,S.B., Araújo,L.A., Pedroso,C.F., Marinho,T.A., Gonçalves,I.A.J., Santos,T.A.P., Pinheiro,R.S., Oliveira,G.A., Batista,K.A.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Journal of Medical and Biological Research
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2022000100301
• topic: COVID-19; SARS-CoV-2; Antimicrobial resistance; Multidrug-resistant bacteria

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused several problems in healthcare systems around the world, as to date, there is no effective and specific treatment against all forms of COVID-19. Currently, drugs with therapeutic potential are being tested, including antiviral, anti-inflammatory, anti-malarial, immunotherapy, and antibiotics. Although antibiotics have no direct effect on viral infections, they are often used against secondary bacterial infections, or even as empiric treatment to reduce viral load, infection, and replication of coronaviruses. However, there are many concerns about this therapeutic approach as it may accelerate and/or increase the long-term rates of antimicrobial resistance (AMR). We focused this overview on exploring candidate drugs for COVID-19 therapy, including antibiotics, considering the lack of specific treatment and that it is unclear whether the widespread use of antibiotics in the treatment of COVID-19 has implications for the emergence and transmission of multidrug-resistant bacteria.